Product Description
CPB532 is a 1+1 bivalent bispecific designed to simultaneously target mouse T cell immunoreceptor with Ig and ITIM domains (TIGIT) and mouse CD25 (IL-2Ralpha). This bispecific was designed to selectively deplete intratumoral Tregs that co-express both CD25 and TIGIT, while sparing most peripheral Tregs and activated effector T cells creating a stronger anti-tumor immune response. CD25 targeting helps identify activated, highly suppressive Tregs in the tumor microenvironment, where CD25 expression is enriched on the most immunosuppressive subset. TIGIT targeting adds tumor selectivity because TIGIT is also enriched on tumor Tregs and marks a suppressive, activated phenotype. Anti-TIGIT x anti-CD25 bispecifics work by co-targeting a double-positive intratumoral Treg population to selectively remove suppressive cells and restore anti-tumor immunity.
* VAT and shipping costs not included. Errors and price changes excepted
